JPRN-UMIN000001395已完成1 期
Phase I clinical study of Glypican-3 peptide vaccine in patients with advanced Hepatocellular carcinoma - Phase I clinical study of Glypican-3 peptide vaccine in patients with Hepatocellular carcinoma
Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East0 个研究点目标入组 33 人开始时间: 2008年9月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Uncontrolled pleural effusion or ascites. 2)Metastatic disease to the brain. 3)There are other malignancies. 4)Active infection excluding HBV, HCV. 5)Positive for HIV. 6)Clinically significant heart disease. (myocardial infarction or unstable angina within the past six months, or uncontrolled cardiac arrhythmias) 7)There are severe complications including cardiac failure, renal failure, liver failure, active gastro-duodenal ulcer, ileus, and uncontrolled Diabetes Mellitus. 8)There is severe psychiatric disorder. 9)Pregnant or lactating woman, who are willing to be pregnant. 10)Past history of severe drug allergy. 11)Immunodeficiency, previous splenectomy, irradiation to the spleen. 12)Ongoing treatment with corticosteroid, or immunosuppressant drugs. 13)Previous allograft transplantation. 14)Responsible doctors judged the patient in appropriate for the trial.
研究者
相似试验
已完成
2 期
A Phase II study of Glypican-3(GPC3) peptide vaccine as adjuvant treatment for Hepatocellular carcinoma(HCC) after Surgical resection or Radiofrequency ablation(RFA)JPRN-UMIN000002614Division of Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East40
已完成
1 期
A Phase I study of Glypican-3(GPC3) Peptide Vaccine for Pediatric Patients with Refractory TumorsRefractory pediatric tumorsJPRN-UMIN000006357Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East15
招募中
1 期
Phase II study of Glypican-3(GPC3) peptide vaccine as treatment for clear cell adenocarcinoma of ovary.JPRN-UMIN000003696Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East140
尚未招募
3 期
Efficacy of the Glicigen – Viusid in the treatment of external genitals anus wart in childreexternal anus genitals wartRPCEC00000097Catálysis S.L.
已完成
不适用
Serum Galectin-3 in AFKCT0005496Korea University Anam Hospital75